Genstruct Partners with Pfizer on Preclinical Drug Analysis | GenomeWeb
NEW YORK (GenomeWeb News) – Informatics company Genstruct said today it will collaborate with Pfizer on current and future preclinical drug safety studies.
Under a new master research agreement, Genstruct will initially work with Pfizer on a systems biology analysis of the biological mechanisms that underlie drug-induced liver injury.
Genstruct President and CEO Keith Elliston said the company has previously worked with Pfizer on oncology, vascular injury, cardiovascular, and metabolic disease.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.